Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PS0P | ISIN: US92764N1028 | Ticker-Symbol:
NASDAQ
26.07.24
21:59 Uhr
10,700 US-Dollar
+0,040
+0,38 %
1-Jahres-Chart
VIR BIOTECHNOLOGY INC Chart 1 Jahr
5-Tage-Chart
VIR BIOTECHNOLOGY INC 5-Tage-Chart

Aktuelle News zur VIR BIOTECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrVir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark2
26.06.Vir Biotechnology, Inc. - 8-K, Current Report5
06.06.Vir Biotechnology (VIR) Up on Positive Data From HDV Study6
05.06.Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?5
05.06.Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 216
05.06.Vir gains on early mid-stage data for hepatitis candidate5
29.05.Vir Biotechnology, Inc. - 8-K, Current Report2
29.05.Vir Biotechnology Appoints Mark Eisner As EVP And Chief Medical Officer2
29.05.Vir Biotechnology names Mark Eisner as chief medical officer2
24.05.Evaluating Vir Biotechnology: Insights From 5 Financial Analysts4
22.05.Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024481- Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST - Vir Biotechnology...
► Artikel lesen
21.05.Vir Biotechnology, Inc.: Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024278Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation....
► Artikel lesen
07.05.Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)8
03.05.Vir Biotechnology, Inc. - 10-Q, Quarterly Report2
03.05.Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript3
03.05.Earnings call: Vir Biotechnology reports Q1 2024 financials, pipeline progress4
02.05.Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results140SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We are excited...
► Artikel lesen
19.04.How Vir found the one: CEO Marianne De Backer5
18.04.Vir Biotechnology, Inc. - 8-K, Current Report 3
26.02.Vir Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1